###### Practice Points

-   Clinically available tyrosine kinase inhibitors (TKIs) are effective in treatment of EGFR-mutated non-small-cell lung carcinoma (NSCLC).

-   Leptomeningeal disease is a known complication of NSCLC with variable manifestations and grim prognosis.

-   Targeted treatment with TKIs may achieve partial control of leptomeningeal metastasis from EGFR-mutated NSCLC.

-   TKIs may alter the radiographic appearance of leptomeningeal disease, requiring a high index of suspicion and utilization of novel cerebrospinal fluid analysis techniques to establish the diagnosis.

EGFR is a transmembrane protein involved with cell proliferation, survival and tumorigenesis \[[@B1],[@B2]\]. Driver EGFR mutations have been identified in non-small-cell lung carcinomas (NSCLCs) \[[@B3]\]. Deletions in exon 19 and *L858R* missense mutations in exon 21 are the most common EGFR mutations known to be activating \[[@B7],[@B8]\]. Tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are effective in treating EGFR-mutant NSCLC as first-line therapy \[[@B4],[@B5],[@B8]\]. However, resistance to first-line TKIs develops, with EGFR *T790M* mutation on exon 20 most commonly detected on repeat biopsy \[[@B15],[@B16]\]. Third-generation TKIs, such as osimertinib, have been designed to overcome *T790M* mutation \[[@B15]\].

Leptomeningeal disease (LMD) -- defined as spread of cancer to the pia mater, arachnoid mater and the subarachnoid space -- is a known complication of NSCLC and carries a poor prognosis, typically if left untreated, in the order of weeks to months \[[@B19]\]. Despite advanced imaging and cerebrospinal fluid (CSF) evaluation techniques, establishing the diagnosis can be challenging \[[@B19]\]. MRI of the neuroaxis is the imaging modality of choice, but a normal MRI does not exclude the diagnosis \[[@B19]\]. Tumor cells can be identified with CSF cytology and this remains the gold standard, however, sensitivity of a single sample is low and repeat CSF analyses may be needed \[[@B19]\].

Emerging technologies such as cell-free DNA (cf-DNA) and utilizing analysis of CSF circulating tumor cells (CTCs) provide new forms of liquid biopsy. Veridex\'s (NJ, USA) CellSearch^®^ is a commercially available assay which can be adapted for the detection of CTCs in CSF, based on the expression of a transmembrane glycoprotein called EpCAM detected in tumors of epithelial origin. A benefit of CTC analysis is that it allows for a quantitative evaluation \[[@B26]\]. Reported sensitivities of EpCAM-based CSF analysis for detection of LMD has been 76--100% \[[@B26]\]. However, EpCAM is not expressed by all solid organ malignancies and thus CTC technology also has its limitations. In contrast, cf-DNA technology relies on DNA released from neoplastic cells \[[@B30]\]. DNA from tumor cells can be detected within the CSF, establishing the diagnosis of LMD. In addition, analysis of CSF cf-DNA can help identify clinically relevant mutations from metastatic and primary nervous system tumors \[[@B30]\].

LMD has been described in patients with EGFR-mutated NSCLC. LMD carries a grim prognosis with an estimated survival of less than 6 months despite treatments such as radiation therapy, intrathecal chemotherapy and systemic chemotherapy \[[@B19],[@B34]\]. Emerging data indicates osimertinib penetrates the blood--brain barrier and may represent a therapeutic option after first-generation TKI failure, especially in the setting of T790M mutation \[[@B34]\]. However, data is limited on the radiographic features of LMD in patients with EGFR mutated TKI-treated NSCLC.

Herein we describe our clinical experience with five patients at Memorial Sloan Kettering Cancer Center (NY, USA) with TKI-treated EGFR-mutated NSCLC who developed LMD while lacking characteristic imaging findings.

Case 1 {#S0001}
======

A 69-year-old man was diagnosed with EGFR exon 19-deleted adenocarcinoma of the lung in December 2015. Staging MRI of the brain revealed numerous parenchymal brain metastases in January 2016. He was started on erlotinib and had excellent early response with resolution of brain metastases on repeat MRI in June 2016. Worsening pulmonary metastasis in November 2016 led to identification of EGFR *T790M* mutation, after which he was transitioned to osimertinib.

Clinical signs of LMD developed in October 2016, with the patient reporting vertical diplopia. In November 2016, he developed jaw weakness. MRI brain performed in November 2016, January and February 2017 showed no radiographic evidence of LMD. CSF cytology identified adenocarcinoma in February 2017, confirming clinically suspected LMD. It was only in October 2017 that MRI brain showed scattered evidence of LMD and MRI spine revealed cauda equina involvement ([Figure 1](#F1){ref-type="fig"}).

![Evolution of radiographic imaging for all cases.\
**(A1 & A2)** Case 1 T1-post contrast MRI brain obtained January 2017 with no evidence of LMD 3 months after onset of vertical diplopia **(A1).** T1-post contrast MRI brain obtained October 2017 with scattered leptomeningeal enhancement (arrows) as the only radiographic evidence of LMD **(A2)**. **(B1 & B2)** Case 2 T1-post contrast MRI brain obtained September 2016 with no evidence of LMD several months after onset of right cranial nerve VII and VIII palsy **(B1).** T1-post contrast MRI brain obtained December 2016 with enhancement along cranial nerve VII (arrow) providing the only radiographic evidence of LMD **(B2)**. **(C1 & C2)** Case 3 T1 post-contrast MRI spine obtained September 2018 with no evidence of LMD **(C1)**. T1 post-contrast MRI spine obtained November 2018 with faint enhancement along conus, providing only radiographic evidence of leptomeningeal disease. D1, D2: Case 4 T1-post contrast MRI brain obtained March 2018 with no evidence of LMD (D1). T1-post contrast MRI brain obtained September 2018 with leptomeningeal enhancement providing first radiographic evidence of LMD **(D2)**. **(E1 & E2)** Case 5 T1-post contrast MRI spine obtained September 2017 with no radiographic evidence of LMD **(E1).** T1-post contrast MRI spine obtained August 2018 with superficial metastasis (arrow) as the only radiographic evidence of LMD **(E2)**.\
MRI: Magnetic resonance imaging; LMD: Leptomeningeal disease.](cns-08-42-g1){#F1}

Case 2 {#S0002}
======

A 69-year-old woman was diagnosed with EGFR exon 19-deleted adenocarcinoma of the lung in July 2015. Initial staging MRI of the brain revealed multiple brain metastases. Patient had no clinical neurologic signs at the time of diagnosis.

She was treated with whole brain radiation therapy in August 2015, followed by stereotactic radiosurgery to additional metastases the following November. She was initially treated with erlotinib but transitioned to osimertinib in March 2016 when biopsy of a liver metastasis revealed an EGFR *T790M* mutation.

Clinical signs of LMD developed in spring 2016 with hearing loss noted in the right ear, suggesting involvement of cranial nerve VIII. MRI brain in June and September 2016 showed no radiographic evidence of leptomeningeal metastasis. Lower motor neuron pattern right facial weakness developed in October 2016 and progressed over the following 2 months. Only in December 2016, repeat MRI brain showed ill-defined enhancing lesions along multiple cranial nerves including right cranial nerves VII and VIII in the internal auditory canal ([Figure 1](#F1){ref-type="fig"}). She was treated with skull base radiation in January 2017. Lumbar puncture performed in March 2017 revealed cytology positive for adenocarcinoma, confirming LMD.

Case 3 {#S0003}
======

A 58-year-old man was diagnosed with EGFR exon 19-deleted adenocarcinoma of the lung in April 2018. At the time of cancer diagnosis, he was found to have a single left posterior midbrain metastasis and associated hydrocephalus, which was treated with a third ventriculostomy and stereotactic radiosurgery.

He was started on osimertinib and bevacizumab in May 2018. LMD was clinically suspected in September 2018 when he developed diplopia and confusion, but MRI brain and spine showed no evidence of leptomeningeal involvement. CSF cytology from November 2018 demonstrated suspicious cells concerning for carcinoma. CSF was also analyzed using the CellSearch assay and 40 CTCs were identified, confirming LMD. In November 2018, repeat MRI spine demonstrated faint leptomeningeal enhancement along the conus and cauda equina nerve roots, providing the only radiographic evidence of LMD. Brain MRI remained negative through to February 2019 ([Figure 1](#F1){ref-type="fig"}).

Case 4 {#S0004}
======

A 60-year-old woman with adenocarcinoma of the lung diagnosed in January 2009 had an EGFR *T790M* mutation in multiple lung biopsies as well as EGFR *L858* mutation in a single left lung nodule. She was initially treated with erlotinib, then transitioned to osimertinib.

LMD was clinically suspected in March 2018 due to persistent vertigo of unclear etiology, but MRI brain and total spine obtained at the time provided no radiographic evidence of leptomeningeal involvement. Patient subsequently developed cognitive difficulty, gait difficulty and incontinence. Lumbar puncture completed in August 2018 revealed cytology positive for adenocarcinoma, confirming the diagnosis of LMD. MRI brain only later in September 2018 demonstrated left cerebellar folia enhancement consistent with leptomeningeal carcinomatosis ([Figure 1](#F1){ref-type="fig"}).

Case 5 {#S0005}
======

A 75-year-old woman was diagnosed with EGFR *L858R* mutated adenocarcinoma of the lung in July 2014. Initial staging MRI of the brain revealed multiple parenchymal metastases and she was started on erlotinib. MRI brain in October 2014 demonstrated resolution of previous areas of enhancement. In February 2016, she received focal radiation therapy to an isolated L5-S1 metastasis. In January 2017, she was started on osimertinib due to progression noted in lungs and peripheral blood positive for *T790M* mutation.

Clinical signs of LMD developed during September 2017 with her reporting severe constipation and urinary retention with overflow incontinence, unexplained by the stable L5-S1 lesion that had been treated with radiation. MRI spine did not show evidence of LMD. MRI brain showed several new parenchymal lesions without definite enhancement. Cytology was negative on lumbar puncture performed in October 2017.

It was only in August 2018 that MRI brain revealed superficial cortical lesions, suggesting radiographic evidence of LMD, and lumbar puncture demonstrated cytology positive for adenocarcinoma ([Figure 1](#F1){ref-type="fig"}).

Discussion {#S0006}
==========

In this case series we describe five patients with EGFR-mutated NSCLC who developed LMD. All five patients received TKIs prior to development of cytology-confirmed LMD. *T790M* mutation was identified in four cases. In all cases, clinical signs of LMD preceded radiographic evidence of leptomeningeal involvement by 2--12 months. [Figure 2](#F2){ref-type="fig"} summarizes representative time course for Case 3.

![Time course from diagnosis of non-small-cell lung carcinoma to radiographic evidence of leptomeningeal disease in Case 3.\
LMD: Leptomeningeal disease; NSCLC: Non-small-cell lung carcinoma.](cns-08-42-g2){#F2}

Observations from this case series have several implications. LMD secondary to EGFR-mutant TKI-treated NSCLC may inherently have minimal radiographic presence, explaining the lack of leptomeningeal enhancement despite presence of clinical symptoms compatible with LMD and positive cytology. On the other hand, use of TKIs may partially control CSF disease, resulting in a paucity of MRI findings. Prior studies have already demonstrated that osimertinib penetrates the blood--brain barrier and may be effective in treating LMD in patients with EGFR *T790M*-mutated NSCLC, thus improving prognosis \[[@B26]\]. In our case series, use of osimertinib may have partially controlled LMD, resulting in a paucity of characteristic radiographic features. This hypothesis may be supported in that, patients in our series developed clinical signs 2--12 months prior to radiographic diagnosis. In one patient in our cohort, bevacizumab may have further altered the radiographic appearance of LMD.

The experience with the patients in our case series also underscores the importance of clinically maintaining a high index of suspicion when diagnosing LMD. Given the low sensitivity of traditional testing methodologies, such as serial MRIs and lumbar punctures, there is a need for liquid biopsies. By incorporating novel methods such as CSF CTC detection and cf-DNA analysis into more routine clinical use, we may be able to better detect LMD \[[@B26]\]. CTC and cf-DNA analysis can potentially be further leveraged to identify actionable mutations, which can have a direct impact on treatment planning \[[@B38],[@B39]\]. Establishing the diagnosis of LMD and characterizing the nature of tumor involvement in the CSF remains important, with implications on systemic treatment, consideration of intrathecal chemotherapy options and symptomatic management including CSF shunting and radiation therapy.

This case series has several limitations. First, this is a retrospective review of patients evaluated at a tertiary care center. Patients were not controlled for treatments prior to initiation of TKI or dosing of the TKIs administered. One patient received bevacizumab concurrently with TKI treatment. Imaging intervals were not standardized with clinicians obtaining MRIs at their discretion.

Nevertheless, we believe that the observation of a lag between the clinical onset of symptoms and radiographic evidence of LMD in patients with TKI-treated EGFR-mutated NSCLC is a clinically important finding, especially as the lag observed could be up to 12 months. The paucity of radiographic features, negative CSF cytology and the halted neurologic progression is not typical of LMD as described in the literature. The revolutionary impact of TKIs may be transforming LMD into a chronic disease state. We hypothesize neurologic dysfunction without radiographic evidence of LMD may be due to low-level disease activity in these patients with chronic leptomeningeal involvement.
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